{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:32:31Z","timestamp":1790332351494,"version":"4.1.0"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2015-03295"],"award-info":[{"award-number":["2015-03295"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["GPO\/275\/12\/20"],"award-info":[{"award-number":["GPO\/275\/12\/20"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["2015-03295"],"award-info":[{"award-number":["2015-03295"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["GPO\/275\/12\/20"],"award-info":[{"award-number":["GPO\/275\/12\/20"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"publisher","award":["2015-03295"],"award-info":[{"award-number":["2015-03295"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"publisher","award":["CSA2016S-1618"],"award-info":[{"award-number":["CSA2016S-1618"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"publisher","award":["GPO\/275\/12\/20"],"award-info":[{"award-number":["GPO\/275\/12\/20"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Long-term antiretroviral treatment (cART) increases the risk of glucose metabolism disorders (GMDs). Genetic variation in drug-metabolizing enzymes and transporters may influence susceptibility to cART-associated GMDs. We conducted a case-control study to investigate the association of pharmacogenetic variations with cART-induced GMDs. A total of 240 HIV patients on long-term efavirenz-based cART (75 GMD cases and 165 controls without GMDs) were genotyped for CYP3A4*1B, CYP3A5 (*3,*6), CYP2B6*6, UGT2B7*2, ABCB1 (c.3435C&gt;T, c.4036A&gt;G), and SLCO1B1 (*1b, *5). GMD cases were defined as the presence of impaired fasting glucose, insulin resistance, or diabetes mellitus (DM). Case-control genotype\/haplotype association and logistic regression analysis were performed by adjusting for age, sex, and BMI. The major CYP3A haplotype were CYP3A5*3 (53.8%), CYP3A4*1B (17.3%), combinations of CYP3A4*1B, and CYP3A5*6 (10.9%), and CYP3A wild type (7%). CYP3A5*6 allele (p = 0.005) and CYP3A5*6 genotype (p = 0.01) were significantly associated with GMD cases. Multivariate analysis indicated CYP3A haplotype as a significant predictor of GMD (p = 0.02) and IFG (p = 0.004). CYP2B6*6 significantly predicted DM (p = 0.03). CYP3A haplotype and CYP2B6*6 genotype are independent significant predictors of GMD and DM, respectively, among HIV patients on long-term EFV-based cART.<\/jats:p>","DOI":"10.3390\/jpm12071087","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:21:50Z","timestamp":1656634910000},"page":"1087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6143-0387","authenticated-orcid":false,"given":"Wondmagegn Tamiru","family":"Tadesse","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulambius Mathias","family":"Mlugu","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital-Huddinge, 14186 Stockholm, Sweden"},{"name":"Department of Pharmaceutics and Pharmacy Practice, School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65014, Tanzania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-6235","authenticated-orcid":false,"given":"Workineh","family":"Shibeshi","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4950-3966","authenticated-orcid":false,"given":"Wondwossen Amogne","family":"Degu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, School of Medicine, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9931-6421","authenticated-orcid":false,"given":"Ephrem","family":"Engidawork","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Pharmacology, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa P.O. Box 9086, Ethiopia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital-Huddinge, 14186 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2016). Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, World Health Organization. [2nd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Desta, A., Biru, T.T., and Kefale, A.T. (2020). Health Related Quality of Life of People Receiving Highly Active Antiretroviral Therapy in Southwest Ethiopia. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0237013"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Yimer, G., Ueda, N., Habtewold, A., Amogne, W., Suda, A., Riedel, K.-D., Burhenne, J., Aderaye, G., Lindquist, L., and Makonnen, E. (2011). Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027810"},{"key":"ref_4","first-page":"499","article-title":"High Plasma Efavirenz Level and CYP2B6*6 Are Associated with Efavirenz-Based HAART-Induced Liver Injury in the Treatment of Na\u00efve HIV Patients from Ethiopia: A Prospective Cohort Study","volume":"12","author":"Yimer","year":"2012","journal-title":"Pharm. J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mugusi, S., Ngaimisi, E., Janabi, M., Minzi, O., Bakari, M., Riedel, K.-D., Burhenne, J., Lindquist, L., Mugusi, F., and Sandstrom, E. (2012). Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0040180"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/hiv.12693","article-title":"Hepatic and Renal Toxicity and Associated Factors among HIV-Infected Children on Antiretroviral Therapy: A Prospective Cohort Study","volume":"20","author":"Tadesse","year":"2019","journal-title":"HIV Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00228-018-2499-0","article-title":"Neuropsychiatric Manifestations among HIV-1 Infected African Patients Receiving Efavirenz-Based CART with or without Tuberculosis Treatment Containing Rifampicin","volume":"74","author":"Mugusi","year":"2018","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mukonzo, J.K., Okwera, A., Nakasujja, N., Luzze, H., Sebuwufu, D., Ogwal-Okeng, J., Waako, P., Gustafsson, L.L., and Aklillu, E. (2013). Influence of Efavirenz Pharmacokinetics and Pharmacogenetics on Neuropsychological Disorders in Ugandan HIV-Positive Patients with or without Tuberculosis: A Prospective Cohort Study. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-261"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14740338.2019.1644317","article-title":"Metabolic Complications Affecting Adipose Tissue, Lipid and Glucose Metabolism Associated with HIV Antiretroviral Treatment","volume":"18","author":"Lagathu","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Tadesse, B.T., Foster, B.A., Chala, A., Chaka, T.E., Bizuayehu, T., Ayalew, F., Meskel, G., Tadesse, S., Jerene, D., and Makonnen, E. (2019). HIV and CART-Associated Dyslipidemia Among HIV-Infected Children. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040430"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tadesse, W.T., Adankie, B.T., Shibeshi, W., Amogne, W., Aklillu, E., and Engidawork, E. (2022). Prevalence and Predictors of Glucose Metabolism Disorders among People Living with HIV on Combination Antiretroviral Therapy. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0262604"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/omi.2017.0006","article-title":"Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation","volume":"21","author":"Petros","year":"2017","journal-title":"OMICS"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Yimer, G., Gry, M., Amogne, W., Makonnen, E., Habtewold, A., Petros, Z., Aderaye, G., Schuppe-Koistinen, I., Lindquist, L., and Aklillu, E. (2014). Evaluation of Patterns of Liver Toxicity in Patients on Antiretroviral and Anti-Tuberculosis Drugs: A Prospective Four Arm Observational Study in Ethiopian Patients. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0094271"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fphar.2020.00026","article-title":"Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations","volume":"11","author":"Mugusi","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ngaimisi, E., Habtewold, A., Minzi, O., Makonnen, E., Mugusi, S., Amogne, W., Yimer, G., Riedel, K.-D., Janabi, M., and Aderaye, G. (2013). Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0067946"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2017.00090","article-title":"HLA-B*57 Allele Is Associated with Concomitant Anti-Tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians","volume":"8","author":"Petros","year":"2017","journal-title":"Front. Pharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/FPC.0000000000000145","article-title":"PharmGKB Summary: Efavirenz Pathway, Pharmacokinetics (PK)","volume":"25","author":"McDonagh","year":"2015","journal-title":"Pharm. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fgene.2012.00236","article-title":"ABCB1 4036A>G and 1236C>T Polymorphisms Affect Plasma Efavirenz Levels in South African HIV\/AIDS Patients","volume":"3","author":"Swart","year":"2012","journal-title":"Front. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/j.1365-2125.2009.03516.x","article-title":"A Novel Polymorphism in ABCB1 Gene, CYP2B6*6 and Sex Predict Single-Dose Efavirenz Population Pharmacokinetics in Ugandans","volume":"68","author":"Mukonzo","year":"2009","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.2217\/pgs.13.111","article-title":"Impact of Pharmacogenetics on CNS Side Effects Related to Efavirenz","volume":"14","author":"Hurtado","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00292","DOI":"10.1002\/edm2.292","article-title":"Increased Risk of Prediabetes among Virally Suppressed Adults with HIV in Central Kenya Detected Using Glycated Haemoglobin and Fasting Blood Glucose","volume":"4","author":"Njoroge","year":"2021","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maganga, E., Smart, L.R., Kalluvya, S., Kataraihya, J.B., Saleh, A.M., Obeid, L., Downs, J.A., Fitzgerald, D.W., and Peck, R.N. (2015). Glucose Metabolism Disorders, HIV and Antiretroviral Therapy among Tanzanian Adults. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134410"},{"key":"ref_23","unstructured":"Feingold, K.R., Anawalt, B., Boyce, A., Chrousos, G., de Herder, W.W., Dhatariya, K., Dungan, K., Hershman, J.M., Hofland, J., and Kalra, S. (2000). Assessing Insulin Sensitivity and Resistance in Humans. Endotext, MDText.com, Inc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"639378","DOI":"10.3389\/fimmu.2021.639378","article-title":"Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells","volume":"12","author":"George","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1476-5381.2010.00866.x","article-title":"Enhanced Oxidative Stress and Increased Mitochondrial Mass during Efavirenz-Induced Apoptosis in Human Hepatic Cells: Mitotoxic Effect of Efavirenz in Human Hepatic Cells","volume":"160","author":"Apostolova","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"112999","DOI":"10.1016\/j.biopha.2022.112999","article-title":"Exposure of Human Immune Cells, to the Antiretrovirals Efavirenz and Lopinavir, Leads to Lower Glucose Uptake and Altered Bioenergetic Cell Profiles through Interactions with SLC2A1","volume":"150","author":"Heaton","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1007\/s11064-013-1165-2","article-title":"8-Hydroxy-Efavirenz, the Primary Metabolite of the Antiretroviral Drug Efavirenz, Stimulates the Glycolytic Flux in Cultured Rat Astrocytes","volume":"38","author":"Brandmann","year":"2013","journal-title":"Neurochem. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e2385","DOI":"10.1097\/MD.0000000000002385","article-title":"Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations","volume":"95","author":"Sinxadi","year":"2016","journal-title":"Medicine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1111\/bph.15309","article-title":"Early or Deferred Initiation of Efavirenz during Rifampicin-Based TB Therapy Has No Significant Effect on CYP3A Induction in TB-HIV Infected Patients","volume":"178","author":"Aklillu","year":"2021","journal-title":"Br. J. Pharm."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chala, A., Tadesse, B.T., Chaka, T.E., Mukonzo, J., Kitabi, E.N., Tadesse, S., Pohanka, A., Makonnen, E., and Aklillu, E. (2021). Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study. J. Pers. Med., 11.","DOI":"10.3390\/jpm11121303"},{"key":"ref_31","first-page":"703","article-title":"Association of a Polymorphism of CYP3A4 with Type 2 Diabetes Mellitus","volume":"20","author":"Yamada","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00228-018-2442-4","article-title":"CYP3A4 and GCK Genetic Polymorphisms Are the Risk Factors of Tacrolimus-Induced New-Onset Diabetes after Transplantation in Renal Transplant Recipients","volume":"74","author":"Shi","year":"2018","journal-title":"Eur. J. Clin. Pharm."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbrc.2005.09.020","article-title":"Phenotype-Genotype Variability in the Human CYP3A Locus as Assessed by the Probe Drug Quinine and Analyses of Variant CYP3A4 Alleles","volume":"338","author":"Sayi","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/em.10199","article-title":"Increased Transcriptional Activity of the CYP3A4*1B Promoter Variant","volume":"42","author":"Amirimani","year":"2003","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_35","first-page":"130","article-title":"Sex and CYP3A5 Genotype Influence Total CYP3A Activity: High CYP3A Activity and a Unique Distribution of CYP3A5 Variant Alleles in Ethiopians","volume":"11","author":"Gebeyehu","year":"2011","journal-title":"Pharm. J."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s12936-017-1914-9","article-title":"Effect of Pharmacogenetics on Plasma Lumefantrine Pharmacokinetics and Malaria Treatment Outcome in Pregnant Women","volume":"16","author":"Mutagonda","year":"2017","journal-title":"Malar. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"712084","DOI":"10.3389\/fphar.2021.712084","article-title":"Effect of Pharmacogenetics Variations on Praziquantel Plasma Concentrations and Schistosomiasis Treatment Outcomes among Infected School-Aged Children in Tanzania","volume":"12","author":"Mnkugwe","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1600-0765.2008.01068.x","article-title":"Role of MDR1 Gene Polymorphisms in Gingival Overgrowth Induced by Cyclosporine in Transplant Patients","volume":"43","author":"Castronovo","year":"2008","journal-title":"J. Periodontal. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.bbapap.2009.02.014","article-title":"A Synonymous Polymorphism in a Common MDR1 (ABCB1) Haplotype Shapes Protein Function","volume":"1794","author":"Fung","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ygeno.2008.03.004","article-title":"Association of a Polymorphism of ABCB1 with Obesity in Japanese Individuals","volume":"91","author":"Ichihara","year":"2008","journal-title":"Genomics"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:41:25Z","timestamp":1760139685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/7\/1087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["jpm12071087"],"URL":"https:\/\/doi.org\/10.3390\/jpm12071087","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}